Sector ratings Alnylam Pharmaceuticals, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-12 pm EDT			5-day change	1st Jan Change
282.85 ^USD	-2.26%		-6.67%	-28.87%

Jun. 10	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
ALNYLAM PHARMACEUTICALS, INC.	37.76B		AA
ELI LILLY AND COMPANY	1,010B		A
JOHNSON & JOHNSON	580B		BBB
ABBVIE INC.	402B	-	AA	-	-
ROCHE HOLDING AG	330B		AA
MERCK & CO., INC.	294B		A
ASTRAZENECA PLC	280B		A
NOVARTIS AG	281B		AAA
NOVO NORDISK A/S	197B		A
AMGEN INC.	192B		A
GILEAD SCIENCES, INC.	156B		AA
PFIZER INC.	149B		A
BRISTOL-MYERS SQUIBB COMPANY	117B		A
VERTEX PHARMACEUTICALS INCORPORATED	113B		AA
SANOFI	106B		AA
GSK PLC	106B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	76.54B		AA
TAKEDA PHARMACEUTICAL COMPANY LIMITED	50.12B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	47.41B		AA
BAYER AG	41.16B		AA
Average	228.38B		AA
Weighted average by Cap.			AA